Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax intensification in EPBCR-low AML
NCT06643962Recruiting
- Sponsor
- Affiliated Hospital of Nantong University
- Start
- Oct 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label trial of venetoclax in acute myeloid leukemia (AML) (2 cohorts), sponsored by Affiliated Hospital of Nantong University. Primary endpoint: Composite Complete Remission Rate at 1 month. Started Oct 2024; status: recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT06643962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06643962.